Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENSET - GENXY -- Ignore unavailable to you. Want to Upgrade?

To: mact who wrote (36)	1/20/2000 6:53:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 200

Genset S.A. (Nasdaq: GENXY - news) CEO Pascal Brandys sees considerable opportunity to identify completely novel pathways for important diseases. ''There is considerably progress in neurobiology but we still don't know what are the molecular mechanisms which are associated with these diseases. Genomics is going to make a huge breakthrough there,'' Brandys states. biz.yahoo.com Newbies to Genset might go to their website for an introduction to the company (newbies include myself) genxy.com an example of pharmacogenomics Genset's collaboration with Abbott for their drug Zyflo® (Zileuton) was the first ever pharmacogenomics drug program established in the industry. genxy.com A little profit taking today I guess... fwiw (two cents) I raised my own target to $40. suite101.com